Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1129-2377
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study ; volume:19 ; number:1 ; day:15 ; month:8 ; year:2018 ; pages:1-8 ; date:12.2018
The journal of headache and pain ; 19, Heft 1 (15.8.2018), 1-8, 12.2018
- Urheber
-
Landy, Stephen
- Beteiligte Personen und Organisationen
-
Munjal, Sagar
Brand-Schieber, Elimor
Rapoport, Alan M.
SpringerLink (Online service)
- DOI
-
10.1186/s10194-018-0882-y
- URN
-
urn:nbn:de:101:1-2018090310161042468895
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Landy, Stephen
- Munjal, Sagar
- Brand-Schieber, Elimor
- Rapoport, Alan M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Episodic Migraine and Older Adults
A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine
Sex and Gender Considerations in Episodic Migraine
Pediatric migraine and episodic syndromes that may be associated with migraine
Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study
Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
Cerebral neurocysticercosis mimicking or comorbid with episodic migraine?
Alterations in pain processing circuitries in episodic migraine
Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial
dfN
Nonspecific periaqueductal gray lesions on T2WI in episodic migraine
The Gut-brain Connection and Episodic Migraine: an Update
Episodic Migraine and Older Adults
A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine
Sex and Gender Considerations in Episodic Migraine
Pediatric migraine and episodic syndromes that may be associated with migraine
Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study
Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
Cerebral neurocysticercosis mimicking or comorbid with episodic migraine?
Alterations in pain processing circuitries in episodic migraine
Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial
dfN
Nonspecific periaqueductal gray lesions on T2WI in episodic migraine
The Gut-brain Connection and Episodic Migraine: an Update
Episodic Migraine and Older Adults
A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine
Sex and Gender Considerations in Episodic Migraine
Pediatric migraine and episodic syndromes that may be associated with migraine
Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study
Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
Cerebral neurocysticercosis mimicking or comorbid with episodic migraine?
Alterations in pain processing circuitries in episodic migraine
Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial
dfN
Nonspecific periaqueductal gray lesions on T2WI in episodic migraine